This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revision | Last revisionBoth sides next revision | ||
home:diseases:celiac [07.20.2019] – [recent research] sallieq | home:diseases:celiac [04.26.2020] – [recent research] sallieq | ||
---|---|---|---|
Line 75: | Line 75: | ||
2018 data show that OLM is an Nrf2 activator, NFkB inhibitor and apoptosis inhibitor in an experimental model of ulcerative colitis. Overall, the study indicates that OLM shows promise as a potential therapy for the treatment of human inflammatory bowel diseases. | 2018 data show that OLM is an Nrf2 activator, NFkB inhibitor and apoptosis inhibitor in an experimental model of ulcerative colitis. Overall, the study indicates that OLM shows promise as a potential therapy for the treatment of human inflammatory bowel diseases. | ||
(({{pubmed> | (({{pubmed> | ||
+ | |||
+ | Research associated with J Tye-Din | ||
+ | |||
+ | |||
{{tag> | {{tag> |